Prosorba Column (Apheresis) - Information and Treatment Indications
Prosorba therapy information and treatment indications. The Prosorba Column (Apheresis) was a treatment option for patients with advanced rheumatoid arthritis who have failed more conservative treatments. The Prosorba Column was discontinued at the end of 2006.
Prosorba column is a possible treatment option for rheumatoid arthritis patients when conventional treatments have failed.
Early diagnosis of rheumatoid arthritis and early, aggressive treatment can help prevent joint damage and deformity. A combination of diagnostic tests, physical examination, and x-ray evidence confirms the diagnosis of rheumatoid arthritis. Take our screening quiz and if you suspect rheumatoid arthritis, consult a rheumatologist.
Various aspects of rheumatoid arthritis make it different from other kinds of arthritis. It is important to learn all that you can about the disease. Better understanding will enhance your ability to manage the condition.
01/27/1999, FDA issues a deficiency letter in regard to the pending approval of Prosorba. On March 15, 1999, the Prosorba column was approved by the FDA for the treatment of rheumatoid arthritis. The Prosorba column was previously approved in 1987 for an unrelated bleeding disorder known as idiopathic thrombocytopenic purpura (ITP).
